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Background: Persistent infection with high-risk types of human pap-
illomavirus (HPV) is the preeminent factor driving the development of
cervical cancer. There are large gaps in knowledge about both the role
of pregnancy in the natural history of HPV infection and the impact
of HPVon pregnancy outcomes.
Methods: This single-site prospective cohort substudy, nested within
an international multisite randomized controlled trial, assessed preva-
lence, incident cases, and persistence of type-specific HPV infection,
and the association between persistence of high-risk HPV infection
with pregnancy outcomes among HIV-infected pregnant women in
Kenya, including HIV transmission to infants. Type-specific HPV was
assessed using a line probe assay in pregnancy and again at 3 months after
delivery. HIV status of children was determined using polymerase chain
reaction at 6 weeks.
Results: In total, 84.1% (206/245) of women had a high-risk HPV infec-
tion at enrollment. Three quarters (157/206) of these infections persisted
postpartum. Persistence of HPV16 and/or HPV18 types was observed in
more than half (53.4%; 39/73) of women with this infection at enrollment.
Almost two-thirds had an incident high-risk HPV infection postpartum,
which was not present in pregnancy (62.5%), most commonly HPV52
(19.0%). After adjustments, no association was detected between persistent
high-risk HPVand preterm birth. All mothers of the 7 cases of infant HIV
infection had persistent high-risk HPV infection (P = 0.044).
Conclusions: High levels of high-risk HPV infection and type-specific
persistence were documented, heightening the urgency of mass role out
of HPV vaccination. The association between HPV persistence and HIV
transmission is a novel finding, warranting further study.
Cervical cancer is a largely preventable disease and WorldHealth Organization (WHO) has recently launched a global
initiative aimed at eliminating the condition.1 At present, cervical
cancer is the second most common cancer among women aged 15
to 44 years in the world. Persistent infection with high-risk (HR)
types of human papillomavirus (HPV) is the preeminent factor
driving the development of cervical cancer.2 More than 75% of
sexually active women will experience HPV infection at some
time in their life, most of whom will clear the infection within
2 years.3 Many factors are thought to promote HPV persistence,
including smoking, age of sexual debut, number of sexual part-
ners, host immunity, host genetics, HIV infection, infection
with other sexually transmitted infections, pregnancy, and use
of oral contraceptives.4–6
Three highly effective recombinant HPV vaccines have
been licensed: a nonavalent vaccine, a quadrivalent vaccine, and
a bivalent vaccine. Although coveragewith HPV vaccines is grow-
ing rapidly in high-income countries, their use in many resource-
constrained settings remains limited.7
Human papillomavirus genotype distribution differs across
geographical areas and populations. Although HPV16 and HPV18
collectively cause 70% of cervical cancer cases in high-income
countries, these patterns vary in other settings.1 A pooled analysis
of more than 15,000 women with cervical abnormalities found
HPV16 to be more than 2.5 times more common in Europe than
in sub-Saharan Africa.8
Human papillomavirus prevalence, multiple HPV infections,
and HPV viral loads have been found to be substantially higher in
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HIV-infected women when compared with HIV-negative women,
including in studies in East Africa.9–12 In addition, compared
with HIV-negative women, precancerous lesions were found to be
3 to 6 times more common in HIV-infected women, including in
one study among HIV-infected pregnant women in Africa.10,13
Human papillomavirus incidence has been reported to be higher
among HIV-infected women, who were also less likely to clear
the infection.5,14
There are many gaps in knowledge about both the role of
pregnancy in the natural history of HPV infection and the impact
of HPVon pregnancy outcomes. Reported adverse pregnancy out-
comes in HPV-infected pregnant women have included preterm
deliveries, intrauterine growth retardation, and placental HPV
infections.15–17 Moreover, there is a paucity of studies investigat-
ing the role of HPV infection on the vertical transmission of
HIV.Mother-to-child transmission of HIV could bemore common
in HPV-infected women owing to the higher HIV viral load levels
observed among pregnant women with HPV and cervical lesions
caused by HPV.18 It is also plausible that HIV takes advantage of
the placental damage caused by HPV to infect the infant, but this
remains unproven.
Considering the overlap in the HPVand HIVepidemics, an
HPV investigation was nested within the Kesho Bora trial, which
was designed primarily to assess the efficacy and safety of a
triple-antiretroviral-drug regimen administered during pregnancy
and continued throughout breastfeeding on Mother-To-Child-
Transmission of HIV (MTCT).19,20 This article presents find-
ings from this substudy, specifically, a longitudinal assessment
of HPV type–specific prevalence, incident infections, persis-
tence and clearance, and the relationship between HR-HPV infec-
tion and birth outcomes among HIV-infected pregnant women
in Kenya.
MATERIALS AND METHODS
Study Population and Intervention
This analysis was nested within the Kesho Bora study
for which the design, population, and results are described
elsewhere.19–21 Data are reported here from 245 HIV-1–
infected pregnant women in Mombasa, Kenya, 1 of the 5 sites
of the Kesho Bora trial. This analysis includes participants en-
rolled in the observational cohorts of the study and the random-
ized controlled trial components of the study, where women
were assigned to a triple antiretroviral regimen or a short-course
dual-drug regimen for prophylaxis against MTCT.20,21
In brief, women were recruited from antenatal clinics and
eligible for the study if they were at 36 weeks' gestation or less,
were confirmed HIV infected, were residing and planning to con-
tinue to reside in the study site catchment area until 2 years after
delivery, and had no evidence of clinically significant conditions.
At the enrollment visit, eligible women were asked to sign an in-
formed consent form, including that for long-term storage of cer-
vical aspirate samples.
Study Procedures
Women were followed up throughout pregnancy and up to
24months after delivery. During the antenatal period, women were
asked to attend the clinic every 2 weeks from enrollment until de-
livery, as well as mother-infant pairs at the same frequency during
the first 8 weeks of the postpartum period, then monthly until
1 year and every 3 months thereafter.
Using face-to-face structured interviews, information in-
cluding sociodemographics, sexual behavior, and reproductive
history was collected at enrollment, and blood samples were taken
for immunological (CD4 cell count) assessments. Children's HIV-1
infection status was determined at the age of 6 weeks using a
quantitative HIV-1 RNA real-time polymerase chain reaction as-
say (Generic HIV-1 Charge Virale, Biocentric, Bandol, France).
All women were screened using a Papanicolaou (Pap)
test at 3 months postpartum. Cytological classification was
done according the Bethesda classification, and women were
given follow-up care as per WHO recommendations.22
Maternal HPV infection and typing was determined at
2 time points, firstly at enrollment and subsequently at
3 months after delivery. Women enrolled in the study were
tested for 28 different HPV genotypes, composed of 14 HR-HPV
and 14 low-risk (LR)HPV. Cervical sampleswere obtained by using
a syringe to introduce 10 mL of normal saline directed at the os to
bath the cervix and ectocervix. The fluid was allowed to pool into
the posterior fornix and aspirated into the same syringe.23 This
was repeated 5 timeswith the same fluid, whichwas then transferred
to a sterile 15-mL conical test tube. The samples were transported to
the laboratory within an hour of collection. Upon arrival at the lab-
oratory, the samples were centrifuged at 3000 rpm for 10 minutes
at 4°C. The acellular fraction was recovered, aliquoted, and stored
at −80°C. The pellet was resuspended in 1 mL of sterile phosphate-
buffered saline and centrifuged at 3000 rpm for 10 minutes at
4°C. The supernatant was discarded, whereas the dry pellet was
stored at −80°C. Human papillomavirus DNAwas extracted from
the resuspended pellet in molecular biology grade water using
the Qiagen DNA mini kit. Human papillomavirus detection
and typing was performed using the INNO-LiPA HPVGenotyp-
ing Extra assay (Innogenetics, Ghent, Belgium) according to the
manufacturer's instructions. The LiPA assay covers 28 HPV geno-
types, including HR-HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68, and 69, and LR-HPV types 6, 11, 26, 40, 43, 44,
53, 54, 66, 70, 71, 73, 74, and 82. The hybridization patterns on
the strips were interpreted by 2 independent readers.
Study Measures
Human papillomavirus–related study end points included
HPV prevalence, incident infections, persistence, and clearance.
We present each of these end points by HPV type, LR-HPV and
HR-HPV categories, and overall measures. Incident HPV infec-
tion was defined as a newly detected HPV genotype at the postde-
livery assessment among women previously negative for that
genotype. Human papillomavirus persistence was defined as a
positive test result for the same genotype at both the antenatal
and the postdelivery assessments, and could be due to reinfec-
tion with the same type. Human papillomavirus clearance was
defined as a positive test result during the antenatal period
followed by a negative test result for the same genotype at the
postdelivery assessment.
Associations between HR-HPV infection and adverse in-
fant outcomes were assessed, including preterm birth (birth before
37 weeks' gestation), low birth weight (any live born infant
weighing <2.5 kg, regardless of gestational age), and infant
HIV infection at 6 weeks of age.
The duration since women discovered their HIV infection
status was dichotomized as less or more than 6 months before
study enrollment. Socioeconomic status quintiles were constructed
based on 9 measures, including household goods, amenities, and
source of water and electricity.
Data Analysis
Data were double entered and analyzed using Stata SE 13
(Stata Corporation, College Station, TX). Descriptive analysis of
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the population characteristics assessed the distribution of
continuous variables and the frequency distribution of cate-
gorical variables in contingency tables. χ2 Tests were used
for analysis of categorical variables, whereas for continuous
variables, we used Student t test or Wilcoxon rank sum tests,
as applicable.
Using multivariable logistic regression models, we investi-
gated whether certain prespecified sociodemographic, clinical,
and obstetric variables of interest were independent predictors of
HR-HPV persistence. We only assessed factors associated with
persistence, as this is the most important risk factor for cervical
cancer. In a separate multivariable logistic regression analysis,
we assessed whether HR-HPV persistence was associated with
preterm delivery, low birth weight, and mother-to-child transmis-
sion of HIV.
Ethics
Ethical approval for study procedures was given by the
Kenyatta National Hospital ethical review board in Kenya, as well
as the ethical review committee at the WHO.
RESULTS
Participant Characteristics
A total of 245 HIV-1–infected pregnant women were en-
rolled in Mombasa, Kenya, and had HPV typing information
available. At enrollment, these women were aged 17 to 42 years,
and most (91.8%) were married or had a regular partner (Table 1).
Gestational age at enrollment was a median 33 weeks (interquartile
range, 32–33 weeks), with 93% of women in their third trimester.
Most women (83.3%; 204/245) had received their HIV diagnosis
within the last 6 months, and 60.4% (148) were classified as clinical
HIV stage 1. Information on sexual behavior was available for 78%
(191/245) of women enrolled in the study. Approximately half of
women (53.9%) were sexually active at 3 months after delivery,
and 40.8% (42/103) of these reported unprotected sexwith any part-
ner since childbirth.
HPV Prevalence
Nearly all women (98.4%; 241/245) enrolled in this study
had infection with 1 or more HR-HPV and/or LR-HPV type.
Among those infected with any HPV type, 85.5% (206/241) car-
ried at least 1 HR-HPV type. In total, 78.5% had more than 1
HPV type.
During pregnancy, the most prevalent HR-HPV types were
HPV52 (43.8%), HPV51 (26.1%), HPV16 (18.0%), HPV35
(13.5%), and HPV18 (13.5%; Fig. 1 and Table 2). At enrollment,
LR-HPV types 6 and 11 were detected in 8.6% and 4.5% of
women, respectively. Of all participants, almost one-third
(29.8%) were carrying HPV16 and/or HPV18 at baseline. Mul-
tiple infections involving HPV6, HPV11, HPV16, and HPV18
(covered by the HPV vaccine Gardasil) were detected in 38.4% of
the study participants.
High-risk HPV types 52, 51, 16, 35, and 18 were still the
most prevalent at 3 months postpartum (Fig. 1). Prevalence of
any HPV infection decreased by 32% over the follow-up period.
None of the baseline sociodemographic characteristics of
the study participants were associated with an increased risk of
HR-HPV infection at baseline, with the exception of marital status
(P = 0.009; Table 1).
HPV Persistence, Clearance, and Incident Infection
The presence of HPV between the antenatal period and
3 months postpartum was assessed for HR-HPV and LR-HPV
types (Table 2). Among participants who had any HR-HPV de-
tected during pregnancy, HR-HPV persistence of 1 or more types
was observed in 76.2% (157/206). Depending on the type, HPV
persistence of the individual HR types varied between 41.7%
and 72.7%. Persistence of 16 and/or 18 types was observed in
more than half (53.4%; 39/73) of women with this infection at en-
rollment.Most demographic or clinical factors were not associated
with HR-HPV persistence (Table 3). When adjusted for potential
confounders, agewas found to be associated with HR-HPV persis-
tence, with women aged 30 to 34 years more likely to have persis-
tent HR-HPV infection than their younger counterparts aged 16 to
24 years (P = 0.013).
Overall, types 11, 68, 51, and 45 were the most likely to be
cleared by infected women, in the proportions of 81.8%, 58.3%,
54.7%, and 50.0%, respectively (Table 2). Of 94 women with 1
or more of infections involving HPV6, HPV11, HPV16, and
HPV18, almost half of the cases (47.9%) cleared 1 or more of
these infections.
The proportion with an HPV incident infection of any HR
type was 62.5%. In decreasing order, the top 5 HR-HPV incident
infections were HPV52 (19.0%, 19 new infections), HPV51
(11.1%, 20 new infections), HPV16 (9.5%, 19 new infections),
HPV35 (7.1%, 15 new infections), and HPV68 (6.1%, 14
new infections). There were 27 new cases of HPV16 and/or
HPV18 (19 acquired HPV18, 9 HPV16, and 1 both HPV16
and HPV18).
Pap Test Results
In total there were 222 valid Pap test results at 3 months af-
ter delivery (7 were not done and 16 results were indeterminate).
Of all women, 27.5% (61/222) had an abnormal result: 24 had
atypical squamous cells of undetermined significance (10.8%),
27 had low-grade squamous intraepithelial lesions (12.2%),
10 had high-grade squamous intraepithelial lesions (4.5%), and
none had evidence of invasive cervical carcinoma. Of 144 women
with persistent HR-HPV infection, 31.3% (45) had an abnormal
Pap test result at 3 months after delivery compared with 20.5%
(16/78) of women with no or nonpersistent HR-HPV. When
adjusted for potential confounders, this difference was not sta-
tistically significant, with women with persistent HR-HPV
being 1.77-fold more likely to have an abnormal Pap test re-
sult (adjusted odds ratio [AOR]; 95% confidence interval
[CI], 0.87–3.60; P = 0.115).
Perinatal and Postnatal Outcomes
Overall, 15.5% (38/245) of childbirths were preterm. There
was no association between persistent HR-HPVand preterm birth
when adjusted for age, education, socioeconomic status, number
of children, duration since HIV diagnosis, CD4 count, WHO clin-
ical staging, and antiretroviral regimen used (AOR, 1.0; 95%
CI, 0.5–2.2; P = 0.99). One in 10 of the infants for whom a birth
weight was recorded (22/222) were categorized as low birth
weight. Babies born to women with persistent HR-HPV were
more likely to weigh less than 2.5 kg at birth (12.8% vs. 4.9%).
However, after controlling for potential confounders, this differ-
ence was no longer statistically significant (AOR, 4.2; 95% CI,
0.84–21.1; P = 0.081).
A total of 9 women transmitted HIV infection to their
children by 6 weeks postpartum. Human papillomavirus data
were not available for 2 of these women. In analysis with the
Vyankandondera et al.
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TABLE 1. Characteristics of HIV-Infected Women and HPV Characteristics at Enrollment (During Pregnancy) in the Kesho Bora Study in
Mombasa, Kenya (N = 245)
Variable
All Women (N = 245),
n/N (%)*
HPV Infection, n/N (%)*
Any High-Risk HPV
Infection (n = 206)
No High-Risk HPV
Infection (n = 39) P
†
Age, mean (SD), y 28.0 (4.9) 28.1 (4.8) 27.2 (5.3) 0.28‡
Education level
Never attended school 12/245 (4.9) 10/206 (4.9) 2/39 (5.1)
Primary 133/245 (54.3) 111/206 (53.9) 22/39 (56.4)
Secondary or higher education 100/245 (40.8) 85/206 (41.3) 15/39 (38.5) 0.95
Current marital status
Married, regular partner 225/245 (91.8) 193/206 (93.7) 32/39 (82.0)
Separated, divorced, widowed 7/245 (2.9) 6/206 (2.9) 1/39 (2.6)
Single 13/245 (5.3) 7/206 (3.4) 6/39 (15.4) 0.009
Current work status
Working 82/245 (33.5) 73/206 (35.4) 9/39 (23.1)
Not working 163/245 (66.5) 133/206 (64.6) 30/39 (76.9) 0.13
Regular partner's current work status
Formal sector 109/225 (48.4) 94/193 (48.7) 15/32 (46.9)
Informal sector 105/225 (46.7) 89/193 (46.1) 16/32 (50.0)
Regular partner not working 11/225 (4.9) 10/193 (5.2) 1/32 (3.1) 0.84
Socioeconomic status,
wealth quintiles
Q1 46/245 (18.8) 37/206 (17.9) 9/39 (23.1)
Q2 52/245 (21.2) 44/206 (21.3) 8/39 (20.5)
Q3 48/245 (19.6) 41/206 (19.9) 7/39 (18.0)
Q4 47/245 (19.2) 36/206 (17.4) 11/39 (28.2)
Q5 (wealthier quintile) 52/245 (21.2) 48/206 (23.3) 4/39 (10.3) 0.27
Duration in relationship, y
<2 y 36/223 (16.1) 34/191 (17.8) 2/32 (6.3)
2–4 77/223 (34.5) 67/191 (35.1) 10/32 (31.3)
≥5 110/223 (49.3) 90/191 (47.1) 20/32 (62.5) 0.16
No. live children
None 82/245 (33.5) 65/206 (31.6) 17/39 (43.6)
1 73/245 (29.8) 64/206 (31.1) 9/39 (23.1)
2 48/245 (19.6) 42/206 (20.4) 6/39 (15.4)
≥3 42/245 (17.1) 35/206 (17.0) 7/39 (18.0) 0.47
Duration since first tested
HIV positive, mo
<6 204/245 (83.3) 174/206 (84.5) 30/39 (77.0)
≥6 41/245 (16.7) 32/206 (15.5) 9/39 (23.1) 0.25
HIV status of regular partner
Never tested 125/226 (55.3) 109/194 (56.2) 16/32 (50.0)
Don't know if ever tested 27/226 (12.0) 25/194 (12.9) 2/32 (6.3)
Ever tested 74/226 (32.7) 60/194 (30.9) 14/32 (43.8) 0.28
HIV negative 32/74 (43.2) 23/60 (38.3) 9/14 (64.3)
HIV positive 37/74 (50.0) 32/60 (53.3) 5/14 (35.7)
Unknown status partner 5/74 (6.8) 5/60 (8.3) 0/14 0.16
CD4 cells, median count (IQR) 350 (275–429) 351 (276–428) 341 (222–451) 0.85§
WHO clinical HIV stage
Stage 1 148/245 (60.4) 121/206 (58.7) 27/39 (69.2)
Stage 2 79/245 (32.2) 72/206 (35.0) 7/39 (18.0)
Stage 3 14/245 (5.7) 9/206 (4.4) 5/39 (12.8)
Stage 4 4/245 (1.6) 4/206 (1.9) 0/39 0.039
Antiretroviral drugs
Antiretroviral therapy 32/245 (13.1) 26/206 (12.6) 6/39 (15.4)
Triple ARV MTCT
prophylaxis
115/245 (46.9) 92/206 (44.7) 23/39 (59.0)
Short-course MTCT
prophylaxis
98/245 (40.0) 88/206 (42.7) 10/39 (25.6) 0.13
*n/N (%) was presented unless otherwise indicated.
†
χ
2 Tests unless otherwise indicated.
‡Student t test.
§Wilcoxon rank sum tests.
ARV MTCT indicates antiretroviral mother-to-child transmission; IQR, interquartile range; WHO, World Health Organization.
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remaining cases, women with persistent HR-HPV were more
likely to transmit HIV to their child than all other women
(P = 0.044), a finding that persisted in multivariate analysis.
In all these 7 cases of mother-to-child transmission, the mothers
had persistent HR-HPV infection (7/157 [4.5%] vs. 0/of 88
women without persistence). An abnormal Pap test result was also
associated with transmission of HIV infection from mother to
child (P = 0.026).
Figure 1. Prevalence of type-specific low-risk and high-risk HPV infections during pregnancy and at 3 months after delivery among
HIV-infected women in Kenya.
TABLE 2. Type-Specific HPV Prevalence in HIV-Infected Kenyan Women at Enrollment (During Pregnancy), and Persistence, Clearance, and
Incident Infections at 3 Months After Delivery
HPV Type
Prevalence at Enrollment,
n/N (%)
Persistence,
n/N (%)
Clearance,
n/N (%)
Incident Infections,
n/N† (%)
Individual low-risk HPV type
6 21/245 (8.6) 11/21 (52.4) 10/21 (47.6) 16/224 (7.1)
11 11/245 (4.5) 2/11 (18.2) 9/11 (81.8) 4/234 (1.7)
Individual high-risk HPV type
16 44/245 (18.0) 26/44 (59.1) 18/44 (40.9) 19/201 (9.5)
18 33/245 (13.5) 17/33 (51.5) 16/33 (48.5) 9/212 (4.3)
31 18/245 (7.4) 12/18 (66.7) 6/18 (33.3) 5/227 (2.2)
33 11/235 (4.7) 6/11 (54.6) 5/11 (45.5) 4/214 (1.9)
35 33/245 (13.5) 24/33 (72.7) 9/33 (27.3) 15/212 (7.1)
39 22/203 (10.8) 12/22 (54.6) 10/22 (45.5) 5/168 (3.0)
45 12/245 (4.9) 6/12 (50.0) 6/12 (50.0) 2/233 (0.9)
51 64/245 (26.1) 29/64 (45.3) 35/64 (54.7) 20/181 (11.1)
52 84/192 (43.8) 55/84 (65.5) 29/84 (34.5) 19/100 (19.0)
56 30/245 (12.2) 16/30 (53.3) 14/30 (46.7) 10/215 (4.7)
58 13/245 (5.3) 8/13 (61.5) 5/13 (38.5) 5/232 (2.2)
59 1/245 (0.4) 1/1 (100) 0/1 (0) 1/244 (0.4)
68 12/241 (5.0) 5/12 (41.7) 7/12 (58.3) 14/228 (6.1)
69 29/245 (11.8) 17/29 (58.6) 12/29 (41.4) 9/215 (4.2)
One or multiple HPV types*
16/18 73/245 (29.8) 39/73 (53.4) 34/73 (46.6) 27/241 (11.2)
6/11/16/18 94/245 (38.4) 49/94 (52.1) 45/94 (47.9) 45/245 (18.4)
Any high-risk HPV 206/245 (84.1) 157/206 (76.2) 49/206 (23.8) 153/245 (62.5)
*Proportion of participants with infection with one or more HPV types. Changes in denominators by HPV type are due to cases of invalid type-specific
results. †Infection with an HPV type at postdelivery that was not present at enrollment, includes only cases with results at both visit.
Vyankandondera et al.
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DISCUSSION
This was the first large-scale longitudinal study investi-
gating the relationship between HPVand pregnancy outcomes
in HIV-infected women in Africa, to our knowledge. The
prevalence of HR-HPV found in this study at enrollment
(84.1%) was 2.5 times higher than that reported in a meta-
analysis among the general population in East Africa and con-
siderably higher than the prevalence reported in a systematic
review of HPV studies in Kenya.24,25
The type-specific prevalence in this study is consistent with
other genotype surveys conducted among HIV-infected women in
East Africa, with the most commonly detected HR genotype being
HPV52.10,12,14 However, the overall distribution of HPV infec-
tions differs from some studies that show HR-HPV types 56 and
58 to be among the most common genotypes in HIV-infected
Kenyan women.10,12 This may, in part, be due to differing
HPV detection methods between studies. Although HPV types
16 and 18 are the most prevalent in the general population as
well as being associated with most cervical cancer cases world-
wide,24,26 our study is consistent with the evidence that indicates
a different type-specific prevalence of HPV in HIV-infected indi-
viduals.10,12,27 The prevalence of HPV16 and/or HPV18 in our
study participants was almost 30%, which is considerably higher
than that in a similar population in Nairobi, where approximately
8% of women had HPV16 and/or HPV18.12 A total of 38.4% of
women in this study were infected with 1 or more of the 4 types
in the quadrivalent HPV vaccine (HPV16, HPV18, HPV6, and
HPV11), and a considerable additional number of women would
be covered by the nonovalent vaccine, which includes HPV52,
for example, the most prevalent HR-HPV type in this population.
However, more than one quarter and more than 1 in 10 women
were infected with HPV51 and HPV35, respectively, neither of
which are included in current HPV vaccines, although some
cross-protection is possible across HPV types.28Given this preva-
lence in an HR population, it may be worth considering the inclu-
sion of these types if future HPV vaccines include additional
HPV types.
Persistent HR-HPV infection is the preeminent risk factor
for cervical cancer.2 Our finding that more than three quarters of
HR-HPV infections in this population of HIV-infected pregnant
women persisted until at least 3 months postpartum is therefore
concerning. It is, however, difficult to directly compare these find-
ingswith other studies because definitions of HPV persistence and
duration of follow-up vary between studies.29
Consistent with the existing literature, the proportion of
LR-HPV cases that were cleared was higher than that with
HR-HPV types (81.4% cleared compared with 58.3%).14 We re-
port type-specific clearance and persistence, such that one woman
who is infected with multiple types at baseline could still be
TABLE 3. Univariable and Multivariable Analyses of Factors Associated With Persistence (or Reinfection) of 1 or More HR-HPV Types Between
Antenatal Period and Postpartum Period Among HIV-Infected Pregnant Women With HR-HPV Infection at Enrollment in Kenya (n = 206)
n/N (%) Crude OR (95% CI) Adjusted OR (95% CI)* P
Age, y
16–24 38/56 (67.9) 1.0 1.0
25–29 53/69 (76.8) 1.6 (0.7–3.5) 1.9 (0.7–4.9) 0.21
30–34 52/62 (83.9) 2.5 (1.0–6.1) 4.0 (1.3–12.5) 0.018
≥35 14/19 (73.7) 1.3 (0.4–4.3) 2.3 (0.5–10.3) 0.27
Education level
Never attended school 8/10 (80.0) 1.0 1.0
Primary 84/111 (75.7) 0.8 (0.2–3.9) 0.7 (0.1–3.7) 0.66
Secondary or higher education 65/85 (76.5) 0.8 (0.2–4.2) 0.6 (0.1–3.7) 0.58
Current marital status
Married, regular partner 146/193 (75.7) 1.0 1.0
Separated, divorced, widowed 5/6 (83.3) 1.6 (0.2–14.2) 0.7 (0.06–7.4) 0.75
Single 6/7 (85.7) 1.9 (0.2–16.6) 2.3 (0.2–24.1) 0.49
Socioeconomic status
1 30/37 (81.1) 1.0 1.0
2 33/44 (75.0) 0.7 (0.2–2.1) 0.8 (0.2–2.5) 0.64
3 33/41 (80.5) 1.0 (0.3–3.0) 1.1 (0.3–3.8) 0.86
4 23/36 (63.9) 0.4 (0.1–1.2) 0.3 (0.1–1.0) 0.054
5 (wealthier quintile) 38/48 (79.2) 0.9 (0.3–2.6) 0.8 (0.2–2.6) 0.71
No. live children
None 47/65 (72.3) 1.0 1.0
1 52/64 (81.3) 1.7 (0.7–3.8) 1.8 (0.7–4.5) 0.20
≥2 58/77 (75.3) 1.2 (0.6–2.5) 0.7 (0.3–2.0) 0.57
Duration since first tested HIV positive, mo
0–5 134/174 (77.0) 1.0 1.0 0.52
≥6 23/32 (71.9) 0.7 (0.3–1.8) 0.7 (0.3–1.9)
WHO clinical HIV staging
Stage 1 90/121 (74.4) 1.0 1.0
Stage 2 56/72 (77.8) 1.2 (0.6–2.4) 1.2 (0.6–2.7) 0.57
Stage 3 or 4 11/13 (84.6) 1.9 (0.4–9.1) 1.8 (0.3–10.6) 0.54
Antiretroviral drugs
Antiretroviral therapy 23/26 (88.5) 3.2 (0.9–11.8) 2.5 (0.6–10.6) 0.21
Triple ARV MTCT prophylaxis 69/88 (78.4) 1.5 (0.8–3.0) 1.6 (0.7–3.4) 0.24
Short MTCT prophylaxis 65/92 (70.7) 1.0 1.0
*Associations were adjusted for all potential confounding factors included in the final multivariable model.
ARV MTCT indicates antiretroviral mother-to-child transmission; OR, odds ratio.
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classified as having cleared a type-specific infection, even when
another type was found to persist. It has been well established in
the literature that HPV clearance is less frequent among HIV-
infected women compared with the general population, and that
they take significantly longer periods of time to clear infec-
tions.5,30 Almost one quarter (23.8%) of the women in this study
had cleared a type-specific HR-HPV infection at 3 months post-
partum. Other studies have shown that high viral load, low CD4
count, smoking and oral contraceptive use are all independent risk
factors for low rates of and prolonged time to HPV clearance.4,30
Our study did not find an association between CD4 count and
HPV persistence, potentially because of the low number of women
with a CD4 count less than 200 cells/mm3. Smoking status and
oral contraceptive use were not measured in this study; however,
the prevalence of oral contraceptives is likely to be low in pregnant
and postpartum women, and smoking is rare among Kenyan
women (estimated to be <1%).31Our findings did show an associ-
ation between age and HPV persistence, with women aged 30 to
34 years more likely to have HR-HPV persistence than women
aged 16 to 24 years. The reason for this is unclear, although po-
tentially these older women may have been infected with HIV
for longer than the younger group, even if they were unaware
of their diagnosis.
This study found that incident infections with any type of
HPVoccurred in 41.2% of women, with the most common 3 types
being consistent with those detected at baseline. This is a similar
finding to a study in Kampala, Uganda, which found that 48%
of HIV-infected pregnant women had had an incident HPV infec-
tion over the course of pregnancy.14 In our study, incident infec-
tions with HPV52, HPV51, and HPV16 were evident in 19%,
11.1%, and 9.5% of women, respectively. Safaeian et al.5 found
similar results in Uganda, with HPV51 and HPV16 having the
highest incidence rates in HIV-infected women. Potentially, if all
the participants in our study had received the quadrivalent HPV
vaccine Gardasil, 18.4% of incident infections might have
been prevented.
In our study, we did not detect an association between
HR-HPV persistence and preterm delivery, unlike in several other
studies.15,16Differences between these findings and our studymay
be related to varying definitions of preterm delivery, difficulties in
accurately estimating gestation in many settings, and already high
risks of preterm delivery in HIV-infected women.32 High-risk
HPV infection has also been associated with premature rupture
of membranes in some studies33 but was not assessed in our study.
We did find an increased risk of low birth weight in infants born to
womenwith persistent HR-HPV infection in bivariate analysis and
a trend in multivariate analysis. These concerns have been raised
in previous studies17 and require further investigation, especially
in settings where low birth weight is a major risk factor for
infant mortality.
This study is the first, to our knowledge, to show an associ-
ation between persistent HR-HPV infection in HIV-infected preg-
nant women and the transmission of HIV from mother to child.
This finding is consistent with evidence that maternal infection
with other sexually transmitted diseases, such as syphilis and her-
pes simplex virus type 2, increases the risk of mother-to-child
transmission of HIV.34,35 In one study, as much as 28% of
mother-to-child transmission of HIV was attributed to herpes sim-
plex virus type 2 infection.34 The mechanism for this is thought to
be related to ulcers and lesions in the genital tract caused by these
infections. Persistent HR-HPV has also been linked with the
presence of cervical abnormalities, with an even stronger asso-
ciation in HIV-infected women.2,26 There are also considerable
synergistic relationships between HPVand HIV, reinforcing the
impact of each other.36 It is important to note that associations
between HPV persistence and MTCT in women receiving anti-
retroviral drugs during pregnancy, as in this study, are likely to
differ from associations in pregnant women not receiving
these drugs.37
There are a number of limitations that must be considered.
Women classified as having HR-HPV persistence at follow-up
could in fact have cleared the infection and then have been
reinfected with the same HR-HPV type. Most previous studies
suggest that women are more likely to clear HPV infections after
childbirth rather than during pregnancy, with most infections be-
ing cleared within 2 years postpartum.30 Our results would differ
from those of an assessment at 12 or 18 months postpartum had
we done so.
In conclusion, our study shows a worryingly high preva-
lence of persistent HR-HPV in HIV-infected women in Mombasa.
The consequent increased risk of cervical cancer in thesewomen is
concerning and warrants further research, heightened access to
HPV vaccination, and considerably increased efforts to prioritize
this public health issue. The nonovalent vaccine holds particular
promise in this setting, although further HPV types may need to
be included to obtain maximum protection. The finding that
HR-HPV persistence is associated with mother-to-child transmis-
sion of HIV is notable and should be investigated further.
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